77 tyme technologies , inc. and subsidiaries consolidated statements of stockholders ' equity for the years ended march 31 , 2019 and 2018 replace_table_token_3_th the notes to the consolidated financial statements are an integral part of these statements 78 tyme technologies , inc. and subsidiaries consolidated statement of cash flows replace_table_token_4_th the notes to the consolidated financial statements are an integral part of these statements . 79 tyme technologies , inc. and subsidiaries notes to consolidated financial statements note 1. nature of business tyme technologies , inc. ( “ tyme tech ” ) is a delaware corporation headquartered in new york , ny , with wholly owned subsidiaries , tyme inc. and luminant biosciences , llc ( “ luminant ” ) ( collectively , “ tyme ” or the “ company ” ) . prior to 2014 , luminant conducted the initial research and development of the company 's therapeutic platform . since january 1 , 2014 , the majority of the company 's research , development and other business activities have been conducted by tyme inc. , which was incorporated in delaware in 2013. tyme is an emerging biotechnology company developing cancer metabolism-based therapies ( cmbts tm ) that are intended to be effective across a broad range of solid tumors and hematologic cancers , while maintaining patient 's quality of life with relatively low toxicity profiles . unlike targeted therapies that attempt to regulate specific pathways within cancer , tyme 's therapeutic approach is designed to take advantage of a cancer cell 's innate metabolic requirements to cause cancer cell death . the company 's lead clinical cmbt program , sm-88 ( racemetyrosine ) , is a novel , oral , monotherapy investigational agent that has been studied in clinical trials for over five years within more than 150 cancer patients . tyme recently completed enrollment for two phase ii clinical trials in prostate and pancreatic cancer , and the company is preparing for pivotal studies for sm-88 in pancreatic cancer during the second half of calendar year 2019. one of these pivotal trials is focused on patients with third-line pancreatic cancer and would be an amendment to the ongoing tyme-88-panc trial ( part 2 ) . the company has also partnered with the pancreatic cancer action network ( “ pancan ” ) to study sm-88 in an adaptive pivotal trial known as precision promise sm starting as second-line monotherapy and could expand to first-line combination therapy with standard of care . a phase ii investigator-initiated trial evaluating sm-88 monotherapy in late-stage sarcomas was launched in may 2019 , under the direction of principal investigator dr. sant chawla and in collaboration with the joseph ahmed foundation ( “ jaf ” ) . all of sm-88 's current clinical programs study sm-88 in use with three low-dose conditioning agents : methoxsalen , phenytoin , and sirolimus ( hereafter , referred to as “ mps ” ) . the company is actively evaluating the expansion of our clinical program to other cancers as sm-88 has demonstrated complete or partial responses in 15 different forms of cancer with a well-tolerated safety profile . the accompanying consolidated financial statements include the results of operations of tyme tech and its wholly owned subsidiaries . liquidity the consolidated financial statements have been prepared on a going-concern basis , which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business . the company has historically funded its operations primarily through equity offerings . during fiscal year 2019 , the company raised gross proceeds of approximately $ 5.8 million through the issuance of its common stock . most recently in april 2019 , the company raised net proceeds of $ 11.3 million after underwriting discounts and before expenses through an underwritten registered offering . previously on november 2 , 2017 , the company entered into an equity distribution agreement ( “ equity distribution agreement ” ) with canaccord genuity inc. ( “ canaccord ” ) , to commence an at-the-market offering ( the “ atm financing facility ” ) pursuant to which the company may , from time to time , subject to certain rules and regulations , sell shares of the company 's common stock , par value $ 0.0001 per share , having an aggregate offering price up to $ 30.0 million , through canaccord , as the company 's sales agent . in the year ended march 31 , 2019 , the company raised approximately $ 5.8 million in aggregate gross proceeds before commissions and expenses through the atm financing facility and paid canaccord aggregate commissions of $ 0.2 million . at march 31 , 2019 , there remained approximately $ 17.9 million of availability to sell shares through the facility . the proceeds of those offerings are being used by the company for continued clinical studies , drug commercialization and development activities and other general corporate and operating expenses . for the year ended march 31 , 2019 , the company had negative cash flow from operations of $ 20.1 million and net loss of $ 33.0 million , which included $ 10.2 million of non-cash expenses , primarily non-cash equity compensation and warrant modification expense . as of march 31 , 2019 , the company had working capital of approximately $ 9.8 million . management has concluded that substantial doubt does not exist regarding the company 's ability to satisfy its obligations as they come due during the twelve-month period following the issuance of these financial 80 statemen ts . this conclusion is based on the company 's assessment of qualitative and quantitative conditions and events , considered in aggregate as of the date of issuance of these financial statements that are known and reasonably knowable . among other relevant co nditions and events , the company has considered its operational plans , liquidity sources , obligations due or expected , funds necessary to maintain the company 's operations , and potential adverse conditions or story_separator_special_tag 77 tyme technologies , inc. and subsidiaries consolidated statements of stockholders ' equity for the years ended march 31 , 2019 and 2018 replace_table_token_3_th the notes to the consolidated financial statements are an integral part of these statements 78 tyme technologies , inc. and subsidiaries consolidated statement of cash flows replace_table_token_4_th the notes to the consolidated financial statements are an integral part of these statements . 79 tyme technologies , inc. and subsidiaries notes to consolidated financial statements note 1. nature of business tyme technologies , inc. ( “ tyme tech ” ) is a delaware corporation headquartered in new york , ny , with wholly owned subsidiaries , tyme inc. and luminant biosciences , llc ( “ luminant ” ) ( collectively , “ tyme ” or the “ company ” ) . prior to 2014 , luminant conducted the initial research and development of the company 's therapeutic platform . since january 1 , 2014 , the majority of the company 's research , development and other business activities have been conducted by tyme inc. , which was incorporated in delaware in 2013. tyme is an emerging biotechnology company developing cancer metabolism-based therapies ( cmbts tm ) that are intended to be effective across a broad range of solid tumors and hematologic cancers , while maintaining patient 's quality of life with relatively low toxicity profiles . unlike targeted therapies that attempt to regulate specific pathways within cancer , tyme 's therapeutic approach is designed to take advantage of a cancer cell 's innate metabolic requirements to cause cancer cell death . the company 's lead clinical cmbt program , sm-88 ( racemetyrosine ) , is a novel , oral , monotherapy investigational agent that has been studied in clinical trials for over five years within more than 150 cancer patients . tyme recently completed enrollment for two phase ii clinical trials in prostate and pancreatic cancer , and the company is preparing for pivotal studies for sm-88 in pancreatic cancer during the second half of calendar year 2019. one of these pivotal trials is focused on patients with third-line pancreatic cancer and would be an amendment to the ongoing tyme-88-panc trial ( part 2 ) . the company has also partnered with the pancreatic cancer action network ( “ pancan ” ) to study sm-88 in an adaptive pivotal trial known as precision promise sm starting as second-line monotherapy and could expand to first-line combination therapy with standard of care . a phase ii investigator-initiated trial evaluating sm-88 monotherapy in late-stage sarcomas was launched in may 2019 , under the direction of principal investigator dr. sant chawla and in collaboration with the joseph ahmed foundation ( “ jaf ” ) . all of sm-88 's current clinical programs study sm-88 in use with three low-dose conditioning agents : methoxsalen , phenytoin , and sirolimus ( hereafter , referred to as “ mps ” ) . the company is actively evaluating the expansion of our clinical program to other cancers as sm-88 has demonstrated complete or partial responses in 15 different forms of cancer with a well-tolerated safety profile . the accompanying consolidated financial statements include the results of operations of tyme tech and its wholly owned subsidiaries . liquidity the consolidated financial statements have been prepared on a going-concern basis , which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business . the company has historically funded its operations primarily through equity offerings . during fiscal year 2019 , the company raised gross proceeds of approximately $ 5.8 million through the issuance of its common stock . most recently in april 2019 , the company raised net proceeds of $ 11.3 million after underwriting discounts and before expenses through an underwritten registered offering . previously on november 2 , 2017 , the company entered into an equity distribution agreement ( “ equity distribution agreement ” ) with canaccord genuity inc. ( “ canaccord ” ) , to commence an at-the-market offering ( the “ atm financing facility ” ) pursuant to which the company may , from time to time , subject to certain rules and regulations , sell shares of the company 's common stock , par value $ 0.0001 per share , having an aggregate offering price up to $ 30.0 million , through canaccord , as the company 's sales agent . in the year ended march 31 , 2019 , the company raised approximately $ 5.8 million in aggregate gross proceeds before commissions and expenses through the atm financing facility and paid canaccord aggregate commissions of $ 0.2 million . at march 31 , 2019 , there remained approximately $ 17.9 million of availability to sell shares through the facility . the proceeds of those offerings are being used by the company for continued clinical studies , drug commercialization and development activities and other general corporate and operating expenses . for the year ended march 31 , 2019 , the company had negative cash flow from operations of $ 20.1 million and net loss of $ 33.0 million , which included $ 10.2 million of non-cash expenses , primarily non-cash equity compensation and warrant modification expense . as of march 31 , 2019 , the company had working capital of approximately $ 9.8 million . management has concluded that substantial doubt does not exist regarding the company 's ability to satisfy its obligations as they come due during the twelve-month period following the issuance of these financial 80 statemen ts . this conclusion is based on the company 's assessment of qualitative and quantitative conditions and events , considered in aggregate as of the date of issuance of these financial statements that are known and reasonably knowable . among other relevant co nditions and events , the company has considered its operational plans , liquidity sources , obligations due or expected , funds necessary to maintain the company 's operations , and potential adverse conditions or

net cash used in operating activities $ ( 20,116,000 ) $ ( 11,879,000 ) net cash used in investing activities $ ( 16,000 ) $ — net cash provided by financing activities $ 5,458,000 $ 30,372,000 operating activities our cash used in operating activities in the year ended march 31 , 2019 totaled $ 20.1 million which is the sum of ( i ) our net loss of $ 33.0 million , adjusted for non-cash expenses totaling $ 10.3 million ( which includes equity-based compensation , warrant modification expense , severance stock option modification , and depreciation and amortization ) , and ( ii ) changes in operating assets and liabilities of $ 2.6 million . our cash used in operating activities in the year ended march 31 , 2018 totaled $ 11.9 million which is the sum of ( i ) our net loss of $ 19.0 million , adjusted for non-cash expenses totaling $ 7.3 million ( which includes equity-based compensation , depreciation and amortization and the issuance of common stock for services ) , and ( ii ) changes in operating assets and liabilities of $ .2 million . investing activities during the year ended march 31 , 2019 investing activities included $ 16 thousand for the purchase of property and equipment . financing activities during the year ended march 31 , 2019 , our finance activities mainly consisted of the following : in the year ended march 31 , 2019 , the company raised approximately $ 5.7 million in net proceeds after sales commissions and expenses of the offering through the atm financing facility via the sale of 2,383,884 shares of our common stock . during the year ended march 31 , 2018 , our financing activities consisted of the following : in the year ended march 31 , 2018 , the company raised approximately $ 5.8 million in net proceeds after sales commissions and expenses of the offering through the atm financing facility via sale of 1,543,364 shares of our common stock . in march 2018 , we raised approximately $ 21.7 million in net proceeds after underwriting commissions and discounts and expenses of the offering through a public offering of 10,350,000 shares of our common stock .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```net cash used in operating activities $ ( 20,116,000 ) $ ( 11,879,000 ) net cash used in investing activities $ ( 16,000 ) $ — net cash provided by financing activities $ 5,458,000 $ 30,372,000 operating activities our cash used in operating activities in the year ended march 31 , 2019 totaled $ 20.1 million which is the sum of ( i ) our net loss of $ 33.0 million , adjusted for non-cash expenses totaling $ 10.3 million ( which includes equity-based compensation , warrant modification expense , severance stock option modification , and depreciation and amortization ) , and ( ii ) changes in operating assets and liabilities of $ 2.6 million . our cash used in operating activities in the year ended march 31 , 2018 totaled $ 11.9 million which is the sum of ( i ) our net loss of $ 19.0 million , adjusted for non-cash expenses totaling $ 7.3 million ( which includes equity-based compensation , depreciation and amortization and the issuance of common stock for services ) , and ( ii ) changes in operating assets and liabilities of $ .2 million . investing activities during the year ended march 31 , 2019 investing activities included $ 16 thousand for the purchase of property and equipment . financing activities during the year ended march 31 , 2019 , our finance activities mainly consisted of the following : in the year ended march 31 , 2019 , the company raised approximately $ 5.7 million in net proceeds after sales commissions and expenses of the offering through the atm financing facility via the sale of 2,383,884 shares of our common stock . during the year ended march 31 , 2018 , our financing activities consisted of the following : in the year ended march 31 , 2018 , the company raised approximately $ 5.8 million in net proceeds after sales commissions and expenses of the offering through the atm financing facility via sale of 1,543,364 shares of our common stock . in march 2018 , we raised approximately $ 21.7 million in net proceeds after underwriting commissions and discounts and expenses of the offering through a public offering of 10,350,000 shares of our common stock .
```    
 Suspicious Activity Report : 77 tyme technologies , inc. and subsidiaries consolidated statements of stockholders ' equity for the years ended march 31 , 2019 and 2018 replace_table_token_3_th the notes to the consolidated financial statements are an integral part of these statements 78 tyme technologies , inc. and subsidiaries consolidated statement of cash flows replace_table_token_4_th the notes to the consolidated financial statements are an integral part of these statements . 79 tyme technologies , inc. and subsidiaries notes to consolidated financial statements note 1. nature of business tyme technologies , inc. ( “ tyme tech ” ) is a delaware corporation headquartered in new york , ny , with wholly owned subsidiaries , tyme inc. and luminant biosciences , llc ( “ luminant ” ) ( collectively , “ tyme ” or the “ company ” ) . prior to 2014 , luminant conducted the initial research and development of the company 's therapeutic platform . since january 1 , 2014 , the majority of the company 's research , development and other business activities have been conducted by tyme inc. , which was incorporated in delaware in 2013. tyme is an emerging biotechnology company developing cancer metabolism-based therapies ( cmbts tm ) that are intended to be effective across a broad range of solid tumors and hematologic cancers , while maintaining patient 's quality of life with relatively low toxicity profiles . unlike targeted therapies that attempt to regulate specific pathways within cancer , tyme 's therapeutic approach is designed to take advantage of a cancer cell 's innate metabolic requirements to cause cancer cell death . the company 's lead clinical cmbt program , sm-88 ( racemetyrosine ) , is a novel , oral , monotherapy investigational agent that has been studied in clinical trials for over five years within more than 150 cancer patients . tyme recently completed enrollment for two phase ii clinical trials in prostate and pancreatic cancer , and the company is preparing for pivotal studies for sm-88 in pancreatic cancer during the second half of calendar year 2019. one of these pivotal trials is focused on patients with third-line pancreatic cancer and would be an amendment to the ongoing tyme-88-panc trial ( part 2 ) . the company has also partnered with the pancreatic cancer action network ( “ pancan ” ) to study sm-88 in an adaptive pivotal trial known as precision promise sm starting as second-line monotherapy and could expand to first-line combination therapy with standard of care . a phase ii investigator-initiated trial evaluating sm-88 monotherapy in late-stage sarcomas was launched in may 2019 , under the direction of principal investigator dr. sant chawla and in collaboration with the joseph ahmed foundation ( “ jaf ” ) . all of sm-88 's current clinical programs study sm-88 in use with three low-dose conditioning agents : methoxsalen , phenytoin , and sirolimus ( hereafter , referred to as “ mps ” ) . the company is actively evaluating the expansion of our clinical program to other cancers as sm-88 has demonstrated complete or partial responses in 15 different forms of cancer with a well-tolerated safety profile . the accompanying consolidated financial statements include the results of operations of tyme tech and its wholly owned subsidiaries . liquidity the consolidated financial statements have been prepared on a going-concern basis , which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business . the company has historically funded its operations primarily through equity offerings . during fiscal year 2019 , the company raised gross proceeds of approximately $ 5.8 million through the issuance of its common stock . most recently in april 2019 , the company raised net proceeds of $ 11.3 million after underwriting discounts and before expenses through an underwritten registered offering . previously on november 2 , 2017 , the company entered into an equity distribution agreement ( “ equity distribution agreement ” ) with canaccord genuity inc. ( “ canaccord ” ) , to commence an at-the-market offering ( the “ atm financing facility ” ) pursuant to which the company may , from time to time , subject to certain rules and regulations , sell shares of the company 's common stock , par value $ 0.0001 per share , having an aggregate offering price up to $ 30.0 million , through canaccord , as the company 's sales agent . in the year ended march 31 , 2019 , the company raised approximately $ 5.8 million in aggregate gross proceeds before commissions and expenses through the atm financing facility and paid canaccord aggregate commissions of $ 0.2 million . at march 31 , 2019 , there remained approximately $ 17.9 million of availability to sell shares through the facility . the proceeds of those offerings are being used by the company for continued clinical studies , drug commercialization and development activities and other general corporate and operating expenses . for the year ended march 31 , 2019 , the company had negative cash flow from operations of $ 20.1 million and net loss of $ 33.0 million , which included $ 10.2 million of non-cash expenses , primarily non-cash equity compensation and warrant modification expense . as of march 31 , 2019 , the company had working capital of approximately $ 9.8 million . management has concluded that substantial doubt does not exist regarding the company 's ability to satisfy its obligations as they come due during the twelve-month period following the issuance of these financial 80 statemen ts . this conclusion is based on the company 's assessment of qualitative and quantitative conditions and events , considered in aggregate as of the date of issuance of these financial statements that are known and reasonably knowable . among other relevant co nditions and events , the company has considered its operational plans , liquidity sources , obligations due or expected , funds necessary to maintain the company 's operations , and potential adverse conditions or story_separator_special_tag 77 tyme technologies , inc. and subsidiaries consolidated statements of stockholders ' equity for the years ended march 31 , 2019 and 2018 replace_table_token_3_th the notes to the consolidated financial statements are an integral part of these statements 78 tyme technologies , inc. and subsidiaries consolidated statement of cash flows replace_table_token_4_th the notes to the consolidated financial statements are an integral part of these statements . 79 tyme technologies , inc. and subsidiaries notes to consolidated financial statements note 1. nature of business tyme technologies , inc. ( “ tyme tech ” ) is a delaware corporation headquartered in new york , ny , with wholly owned subsidiaries , tyme inc. and luminant biosciences , llc ( “ luminant ” ) ( collectively , “ tyme ” or the “ company ” ) . prior to 2014 , luminant conducted the initial research and development of the company 's therapeutic platform . since january 1 , 2014 , the majority of the company 's research , development and other business activities have been conducted by tyme inc. , which was incorporated in delaware in 2013. tyme is an emerging biotechnology company developing cancer metabolism-based therapies ( cmbts tm ) that are intended to be effective across a broad range of solid tumors and hematologic cancers , while maintaining patient 's quality of life with relatively low toxicity profiles . unlike targeted therapies that attempt to regulate specific pathways within cancer , tyme 's therapeutic approach is designed to take advantage of a cancer cell 's innate metabolic requirements to cause cancer cell death . the company 's lead clinical cmbt program , sm-88 ( racemetyrosine ) , is a novel , oral , monotherapy investigational agent that has been studied in clinical trials for over five years within more than 150 cancer patients . tyme recently completed enrollment for two phase ii clinical trials in prostate and pancreatic cancer , and the company is preparing for pivotal studies for sm-88 in pancreatic cancer during the second half of calendar year 2019. one of these pivotal trials is focused on patients with third-line pancreatic cancer and would be an amendment to the ongoing tyme-88-panc trial ( part 2 ) . the company has also partnered with the pancreatic cancer action network ( “ pancan ” ) to study sm-88 in an adaptive pivotal trial known as precision promise sm starting as second-line monotherapy and could expand to first-line combination therapy with standard of care . a phase ii investigator-initiated trial evaluating sm-88 monotherapy in late-stage sarcomas was launched in may 2019 , under the direction of principal investigator dr. sant chawla and in collaboration with the joseph ahmed foundation ( “ jaf ” ) . all of sm-88 's current clinical programs study sm-88 in use with three low-dose conditioning agents : methoxsalen , phenytoin , and sirolimus ( hereafter , referred to as “ mps ” ) . the company is actively evaluating the expansion of our clinical program to other cancers as sm-88 has demonstrated complete or partial responses in 15 different forms of cancer with a well-tolerated safety profile . the accompanying consolidated financial statements include the results of operations of tyme tech and its wholly owned subsidiaries . liquidity the consolidated financial statements have been prepared on a going-concern basis , which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business . the company has historically funded its operations primarily through equity offerings . during fiscal year 2019 , the company raised gross proceeds of approximately $ 5.8 million through the issuance of its common stock . most recently in april 2019 , the company raised net proceeds of $ 11.3 million after underwriting discounts and before expenses through an underwritten registered offering . previously on november 2 , 2017 , the company entered into an equity distribution agreement ( “ equity distribution agreement ” ) with canaccord genuity inc. ( “ canaccord ” ) , to commence an at-the-market offering ( the “ atm financing facility ” ) pursuant to which the company may , from time to time , subject to certain rules and regulations , sell shares of the company 's common stock , par value $ 0.0001 per share , having an aggregate offering price up to $ 30.0 million , through canaccord , as the company 's sales agent . in the year ended march 31 , 2019 , the company raised approximately $ 5.8 million in aggregate gross proceeds before commissions and expenses through the atm financing facility and paid canaccord aggregate commissions of $ 0.2 million . at march 31 , 2019 , there remained approximately $ 17.9 million of availability to sell shares through the facility . the proceeds of those offerings are being used by the company for continued clinical studies , drug commercialization and development activities and other general corporate and operating expenses . for the year ended march 31 , 2019 , the company had negative cash flow from operations of $ 20.1 million and net loss of $ 33.0 million , which included $ 10.2 million of non-cash expenses , primarily non-cash equity compensation and warrant modification expense . as of march 31 , 2019 , the company had working capital of approximately $ 9.8 million . management has concluded that substantial doubt does not exist regarding the company 's ability to satisfy its obligations as they come due during the twelve-month period following the issuance of these financial 80 statemen ts . this conclusion is based on the company 's assessment of qualitative and quantitative conditions and events , considered in aggregate as of the date of issuance of these financial statements that are known and reasonably knowable . among other relevant co nditions and events , the company has considered its operational plans , liquidity sources , obligations due or expected , funds necessary to maintain the company 's operations , and potential adverse conditions or

